Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PP-43 is a topical ophthalmic lubricant developed by Protech Remedies (also known as Protech Therapeutics) for the treatment of dry eye disease. The formulation contains 0.4% w/v Polyethylene Glycol as its active ingredient, which serves as an ocular lubricant to provide temporary relief from burning, irritation, and discomfort caused by dry eyes. It is specifically marketed as a preservative-free (BAK-free) formulation, making it suitable for patients who are sensitive to benzalkonium chloride. The drops work by lubricating the ocular surface, stabilizing the tear film, and helping to reduce redness and swelling associated with dry eye symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PP-43.